The minimum would be in line with what other (Blincycto) leukemia drugs have been acquired for. So about 1.2 billion, (assuming success in the clinic for OXS-1550 or OXS-3550).
Maximum. In the ABSOLUTE best case scenario over 10. HOWEVER this would be contingent upon success in the clinic for SOLID TUMORS using the TriKE platform. Listen to the interview in the link below. Dr. Jeffery Miller, says the holy grail not just for TriKE but for any platform is solid tumors. Solid tumors make up a little over 75% of cancer. And so that means should their be success in the clinic for solid tumors. That the TriKE platform could be used for multiple different types of cancers and also leukemia. DON'T COUNT ON THIS HAPPENING THOUGH THIS IS VERY UNLIKELY TO HAPPEN
In terms of what I think the company will be acquired for? I think what will happen is the same thing is what happened with the new ceos previous company Chase. Oxis will be acquired before any of its drug have finished their trials for 500 million. However, assuming continued success in the trials, That amount could easily exceed 2 billion upon achieving certain milestones. (I.E moving into phase 3 potentially a royalty off sales once the drug is approved)
Finally, I'm going to assume a 1 for 100 reverse split. I believe once they publicly announce data from the OXS-1550, oxis share price will reach 10 cents a share. At this price they will do a reverse split up list to the nasdaq and do an ipo at $10 a share. Averse a reverse split there will be 4 million shares outstanding, and by the time the company is acquired there will be 60 million. (Additional selling of shares needed to fund the continuing trials and to compensate management.)
Here's the good news, thank God Cataldo is gone, the new management will not allow 750 million outstanding shares. I am sure Dr. Kathleen has no interest in running a penny stock. And once she officially becomes ceo, she will up list the company right away.
Sorry didn't answer this earlier thought all there was was (I agree with you!)
News 
Market Data 
Discover 
